Consumers are rethinking dental health. They’re looking beyond whitening and freshness, towards oral probiotics that support long-term gum and immune health. Yet formulators still face a clinical gap: periodontal therapy can remove harmful bacteria, but it doesn’t rebuild the beneficial microbes needed for resilience. That’s why relapse rates remain high, and why demand is rising for probiotics that can rebalance the oral microbiome and sustain gum health.
This whitepaper explores how BLIS M18™, an oral probiotic strain backed by new clinical data, addresses this need - positioning brands at the forefront of the next wave in oral wellness.
